(PSTV) Plus Therapeutics, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(PSTV) Plus Therapeutics, Inc. Complete Analysis Pack
Plus Therapeutics' Business Model Blueprint
Unlock the full strategic blueprint behind Plus Therapeutics, Inc.'s business model. This concise, in-depth Business Model Canvas reveals how the company creates value, builds partnerships, and positions itself in a specialized biotech market. Ideal for investors, analysts, and strategists who want actionable insight—get the full version today.
Partnerships
NanoTx, Corp. license
Plus Therapeutics licenses NanoTx, Corp.’s glioblastoma program to advance and commercialize another CNS oncology asset, expanding its pipeline beyond R-186 NL. This kind of external IP deal is key for a small biotech, since it broadens shot count without building every program in-house.
CNS trial sites
Plus Therapeutics, Inc. depends on academic neuro-oncology CNS trial sites because recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers are rare and need neurosurgical expertise, imaging, and investigators on site. Leptomeningeal metastases affect about 5% of cancer patients, so these centers are critical for enrollment, protocol execution, and fast patient access.
Radiopharmaceutical CDMOs
Rhenium-186 therapies need tight isotope handling because Rhenium-186 has a 90.6-hour half-life, so CDMOs help Plus Therapeutics, Inc. with isotope processing, formulation, and GMP release. These partners are critical for clinical trial material and scale-up, especially as radiopharma manufacturing can’t afford delays.
CROs
CROs handle multi-site trial ops, monitoring, and data capture, which matters for Plus Therapeutics, Inc. as a small clinical-stage oncology company. In cancer drug development, CRO support is standard because studies often span many sites and require tight safety oversight.
- Reduces in-house workload
- Supports multi-site execution
- Improves data quality
- Fits oncology norms
Hospitals and pediatric cancer centers
Hospitals and pediatric cancer centers are Plus Therapeutics, Inc.'s core partners because most CNS cancer care happens in these high-acuity settings, where referral paths, MRI access, and tumor boards help route rare cases fast. These centers matter because pediatric CNS tumors are uncommon and need specialist teams that can diagnose, image, and treat them in one place.
- Primary site for CNS cancer treatment
- Supports referrals and imaging
- Critical for rare, specialized cases
Plus Therapeutics’ Partner Network Advances Rare Brain Cancer Programs
Plus Therapeutics, Inc. relies on licensed IP, academic CNS trial sites, CROs, and CDMOs to move rare brain-cancer programs from lab to clinic. For glioblastoma, leptomeningeal metastases, and pediatric CNS tumors, these partners cut development risk and give access to specialist care, isotope handling, and trial execution.
| Partner | Why it matters | Key data |
|---|---|---|
| NanoTx | Pipeline expansion | External CNS asset |
| Academic sites | Rare-case enrollment | LM affects about 5% |
| CDMOs | Radiopharma supply | Rhenium-186 half-life 90.6h |
What is included in the product
Detailed Word Document
A concise Business Model Canvas for Plus Therapeutics, mapping its radiopharmaceutical strategy, partnerships, and revenue pathway for investors and analysts.
Customizable Excel Spreadsheet
Quickly maps Plus Therapeutics’ pain-relief model into a one-page business snapshot.
Reference Sources
Provides a traceable source trail for Plus Therapeutics, Inc., helping validate key claims and support faster, more confident decisions.
Activities
R-186 NL development
Plus Therapeutics is advancing Rhenium-186 NanoLiposome (RNL), a patented intrathecal radiotherapy, through formulation work, dose optimization, and clinical testing for hard-to-treat CNS tumors. The program has moved through Phase 1/2 studies and is now being built around safety, delivery, and tumor-control data to support later-stage development.
NanoTx glioblastoma program
Plus Therapeutics, Inc. is advancing NanoTx glioblastoma toward commercialization through program management, scientific review, and regulatory planning, with the aim of turning it into a market-ready CNS cancer therapy. It also gives Plus Therapeutics, Inc. a second CNS oncology asset, alongside its broader brain-tumor pipeline.
Clinical trial execution
Plus Therapeutics, Inc. executes clinical trials across 3 core CNS programs: recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer. That means site activation, enrollment, and safety follow-up, which is essential in small, high-risk studies where leptomeningeal metastases affects about 5% of cancer patients and recurrent glioblastoma still has median survival measured in months.
Radiopharmaceutical manufacturing
Radiopharmaceutical manufacturing is a CMC-heavy activity for Plus Therapeutics, Inc. because the rhenium-based nanoliposome needs tightly controlled batch production, sterility, and release testing before clinical use. In its 2025 clinical supply work, this means small-run GMP lots, with each dose cleared through quality checks that directly support trial readiness.
- Controlled batch production
- Quality and release testing
- CMC supports clinical supply
Regulatory and commercialization prep
Plus Therapeutics, Inc. must keep FDA filings, safety datasets, and launch plans ready as its lead CNS oncology program advances, because radiopharmaceuticals face tight CMC, dose, and radiation-safety review. With 1 core market-introduction path to protect, this work links trial readouts to approval steps and later commercial rollout.
- FDA submissions must stay current.
- Safety data drives oncology review.
- Launch prep supports market entry.
Plus Therapeutics Advances 3 CNS Programs With Tight GMP Control
Plus Therapeutics, Inc. focuses on RNL formulation work, GMP batch production, and release testing, since each clinical dose needs tight CMC control before use. It also runs site activation, enrollment, and safety follow-up across 3 CNS programs: recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer.
| Key activity | Data point |
|---|---|
| CNS trials | 3 programs |
| LM incidence | About 5% of cancer patients |
| Supply | Small-run GMP lots |
Preview Before You Purchase
Business Model Canvas
The Plus Therapeutics, Inc. Business Model Canvas preview you see here is the exact same document you’ll receive after purchase. This is not a sample or mockup—it’s a live view of the final file, with the same structure, formatting, and content. Once you complete your order, you’ll get full access to this same ready-to-use document for editing, presenting, or sharing.
Resources
Patented R-186 NL
Rhenium-186 NanoLiposome (R-186 NL) is Plus Therapeutics, Inc.'s flagship patented radiotherapy for hard-to-treat CNS cancers, and the patent estate is a core moat. The platform uses rhenium-186, a beta emitter with a 3.7-day half-life, to target tumors while protecting healthy brain tissue.
NanoTx license rights
Plus Therapeutics, Inc. uses NanoTx license rights to access a glioblastoma asset without funding all development in-house, which matters in a capital-heavy biotech model. Glioblastoma still has a median survival of about 14 to 16 months, so licensed rights can speed pipeline breadth and focus cash on late-stage work.
CNS oncology pipeline
Plus Therapeutics, Inc. keeps its CNS oncology pipeline tight: recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. That focus lets Company spend scarce R&D and regulatory dollars on a few hard CNS indications, while giving investors a clear thesis in markets with low survival rates, such as glioblastoma’s roughly 15-month median OS.
Austin headquarters
Plus Therapeutics, Inc. is headquartered in Austin, Texas, and that site supports corporate, clinical, and administrative work while anchoring its public-company reporting and governance. For a small biotech, keeping these functions in one location helps management stay close to clinical execution and SEC disclosure duties.
- Austin base for corporate, clinical, admin tasks
- Supports public-company reporting and governance
- Central hub for management oversight
Scientific and regulatory know-how
Plus Therapeutics, Inc. depends on scientific and regulatory know-how because clinical-stage radiopharmaceuticals need chemistry, trial, CMC (chemistry, manufacturing, and controls), and FDA filing expertise. This internal know-how helps guide trial design, manufacturing oversight, and regulatory submissions for complex oncology assets.
It is a core resource because one missed step can delay a study or filing.
- Supports trial design and protocol quality
- Oversees radiopharmaceutical manufacturing
- Strengthens FDA and IND filings
- Helps advance oncology assets
Plus Therapeutics’ IP and CNS expertise power a focused brain cancer pipeline
Key resources are Plus Therapeutics, Inc.'s R-186 NL patent estate, NanoTx license rights, and tight CNS oncology know-how. These assets support a focused pipeline in recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer, where median glioblastoma survival is about 14 to 16 months.
| Resource | Why it matters |
|---|---|
| R-186 NL patents | Core IP moat |
| NanoTx rights | Expand pipeline |
| CNS expertise | Supports trials and FDA work |
Value Propositions
Targeted CNS radiotherapy
Plus Therapeutics, Inc. targets CNS tumors with localized radiotherapy, aiming to hit hard-to-treat cancers in the brain and spine while sparing healthy tissue. That matters because glioblastoma five-year survival is still about 7%, so a more precise treatment option fits a high-need, high-risk setting.
Recurrent glioblastoma focus
Recurrent glioblastoma has few effective options and median survival after recurrence is often under 9 months. Plus Therapeutics is building a therapy for this exact setting, which makes the asset clinically relevant to a high-need group in one of the deadliest brain cancers, where 5-year survival remains below 10%.
Leptomeningeal metastases option
Leptomeningeal metastases are a severe end-stage complication of advanced cancer, affecting about 5% of patients with solid tumors and often leaving survival in the 3-6 month range. Plus Therapeutics, Inc. is developing R-186 NL for this niche, where few therapies are purpose-built, which can make a targeted treatment a strong value proposition.
Pediatric brain cancer potential
Plus Therapeutics, Inc. targets pediatric brain cancers with its radiotherapeutic platform, a niche where dosing and safety must be tighter than in adults. Pediatric CNS tumors are rare but serious, and a separate option matters because treatment choices are limited and often surgery-plus-radiation based.
- Rare pediatric CNS market
- Needs child-specific dosing
- Radiotherapy may add choice
Patented nanoliposome platform
Plus Therapeutics, Inc.'s patented nanoliposome platform is a core differentiator because it helps deliver the radioactive payload in a controlled way, which can improve targeting and limit off-target exposure. That platform design sits at the center of the value proposition in its Phase 2 CNS cancer programs.
- Controlled radioactive delivery
- Patented nanoliposome design
- Core to differentiation
Plus Therapeutics Targets Deadly Rare CNS Tumors With Precision Radiation
Plus Therapeutics, Inc. offers localized radiotherapy for CNS tumors, aiming to deliver radiation where it is needed and limit damage to healthy tissue. Its edge is clear in ultra-rare, high-unmet-need settings like recurrent glioblastoma and leptomeningeal metastases, where survival can be only 3-9 months.
| Value driver | Data point |
|---|---|
| Glioblastoma 5-year survival | ~7% |
| Leptomeningeal metastases | ~5% of solid tumors |
| Median survival after recurrence | <9 months |
Customer Relationships
Physician-led treatment
Brain and other CNS cancers make up about 1.3% of U.S. new cancer cases, so Plus Therapeutics, Inc. depends on a small pool of neuro-oncologists and neurosurgeons to decide who gets treated. That makes the customer relationship highly expert-led, with adoption driven by specialist trust, clinical evidence, and referral patterns.
Trial-site coordination
Trial-site coordination is central for Plus Therapeutics, Inc. because early-stage oncology studies depend on investigators and coordinators to screen, consent, and schedule patients at each site; in Phase 1/2 trials, even small enrollment slippage can delay data reads and cash use. The company’s value here is tight site support, since patients enter studies only when sites keep referrals, imaging, and protocol steps moving on time.
Investigator collaboration
Plus Therapeutics, Inc. relies on experienced investigators to run protocols and interpret data, which matters in rare cancers where patient pools are tiny; leptomeningeal metastasis affects about 5%-8% of people with solid tumors. Strong investigator ties also help the company generate publishable data and build scientific credibility.
Partner development agreements
Plus Therapeutics, Inc. uses partner development agreements to manage its NanoTx licensing and development work through contracts, milestones, and shared technical work. This B2B link extends the Company Name beyond internal R&D and ties progress to partner execution, which matters in a business still driven by clinical development and external know-how.
- Contract-based NanoTx collaboration
- Milestone-linked development control
- Shared technical delivery
- Extends beyond internal R&D
Investor communication
Plus Therapeutics, Inc. keeps Investor communication active through SEC filings, earnings materials, and corporate updates, which is standard for a public company with recurring market disclosure duties. Investor relations support the ongoing shareholder relationship by keeping the market informed on results, financing, and pipeline progress.
- SEC filings and earnings materials
- Corporate updates for shareholders
- Investor relations as ongoing contact
Specialist-Led Trust Drives Plus Therapeutics' CNS Cancer Strategy
Plus Therapeutics, Inc. keeps customer ties tight and specialist-led, since brain and other CNS cancers are rare and decisions sit with a small set of neuro-oncologists, neurosurgeons, and trial investigators. In this model, trust, protocol support, and fast site coordination matter more than broad sales reach.
| Driver | Key data |
|---|---|
| U.S. brain and other CNS cancers | About 1.3% of new cases |
| Leptomeningeal metastasis | About 5%-8% of solid tumor patients |
| Relationship base | Specialists, sites, investors |
Channels
Neuro-oncology trial sites
Plus Therapeutics, Inc. uses specialty neuro-oncology trial sites as its main clinical channel for CNS cancers. These sites connect the company to the small U.S. pool of about 25,000 new primary malignant brain and other CNS tumor cases a year, while also providing physician oversight and protocol execution for studies like Rhenium Obisbemeda.
Academic medical centers
Academic medical centers are key for Plus Therapeutics, Inc. in rare brain cancers: the NCI reports about 25,000 malignant brain and other CNS tumors each year in the U.S., and these centers deliver MRI, neurosurgery, and multidisciplinary tumor boards. They also anchor early clinical research, where Plus Therapeutics, Inc. can run first-in-human and small-patient studies.
Children's cancer hospitals
Plus Therapeutics depends on children's cancer hospitals and pediatric oncology programs to enroll and follow up pediatric brain tumor patients, since these centers provide the sedation, imaging, neuro-oncology, and long-term monitoring kids need. Childhood cancer affects about 400,000 children worldwide each year, so access to a small network of specialized hospitals can determine trial speed and data quality.
Licensing and partnership networks
Plus Therapeutics uses licensing and partner ties, including the NanoTx agreement, to move assets through external collaboration instead of building every step in-house. This matters in a small biotech model, where one licensed platform can reach clinic and market faster than a stand-alone commercial buildout.
- Uses licensing to speed asset development
- Relies on external partners, not a big sales force
- NanoTx is a key collaboration channel
SEC and company communications
SEC and company communications are a core channel for Plus Therapeutics, Inc., reaching investors, analysts, and partners through 3 main filing types: 10-K, 10-Q, and 8-K. These updates cover development progress, cash use, and trial milestones, so the market can track the company’s clinical and financial execution in near real time.
- 10-K, 10-Q, 8-K filings
- Investor and partner reach
- Trial and cash updates
Plus Therapeutics Reaches CNS Cancer Patients Through Specialty Trial Sites
Plus Therapeutics, Inc. reaches CNS cancer patients mainly through specialty neuro-oncology trial sites and academic medical centers, which support MRI, neurosurgery, and protocol-led enrollment. It also uses pediatric cancer hospitals for child studies and SEC filings for investors and partners.
| Channel | Use | Data |
|---|---|---|
| Trial sites | CNS enrollment | 25,000 U.S. cases |
| SEC filings | Investor reach | 10-K, 10-Q, 8-K |
Customer Segments
Recurrent glioblastoma patients
Recurrent glioblastoma patients are the core target for Plus Therapeutics, Inc.’s R-186 NL, a therapy built for this severe CNS cancer. The unmet need is extreme: glioblastoma has a 5-year relative survival rate of about 7%, and after recurrence, median survival is often only 6 to 9 months.
Leptomeningeal metastases patients
Leptomeningeal metastases patients are a rare, hard-to-treat niche for Plus Therapeutics, Inc. In the U.S., the condition affects about 5% of solid-tumor cancer patients, or roughly 10,000-15,000 people a year, and median survival is often only 3-6 months without effective control.
This makes the segment small but high-need, which fits Plus Therapeutics, Inc. radiotherapy focus.
Pediatric brain cancer patients
Pediatric brain cancer patients are a distinct segment because children need age-appropriate dosing, safety, and long-term neurodevelopment follow-up; in the U.S., about 4,000 children and teens are diagnosed with brain or other central nervous system tumors each year. Plus Therapeutics includes this group in its pipeline focus, where treatment design must fit smaller bodies and different risk profiles.
Neuro-oncologists and neurosurgeons
Neuro-oncologists and neurosurgeons are Plus Therapeutics, Inc.'s key prescribers and trial leaders; they judge MRI findings, tumor burden, and surgical fit for the roughly 90,000 U.S. brain tumor cases seen each year. Their buy-in drives both real-world use and enrollment in Plus Therapeutics, Inc.'s studies.
- Lead treatment choice
- Control trial referrals
- Set imaging-based eligibility
Biopharma licensing partners
Plus Therapeutics also targets biopharma licensing partners, mainly pharma and biotech firms that can bring in external assets or co-develop programs. This matters because licensing can widen the pipeline without funding every asset in-house, and it fits a model where partnership deals can speed development and share risk.
- Licensing adds external assets
- Partners can co-develop programs
- Helps expand the pipeline
Plus Therapeutics Targets Deadly Brain Cancer Gaps
Plus Therapeutics, Inc. serves high-need cancer niches: recurrent glioblastoma, leptomeningeal metastases, and pediatric CNS tumors, where survival is often measured in months and treatment options are limited. Its main gatekeepers are neuro-oncologists, neurosurgeons, and licensing partners, who drive trials, referrals, and pipeline reach.
| Segment | Key data |
|---|---|
| Glioblastoma | ~7% 5-year survival |
| LM | ~10,000-15,000 U.S. cases/year |
Cost Structure
Clinical trials
Clinical trials are a major cost for Plus Therapeutics, Inc.: oncology studies often run about $10 million to $20 million per phase, with site management, monitoring, imaging, and long patient follow-up driving spend. Rare CNS cancers can push per-patient costs higher because enrollment is slow and each case needs more specialized testing and care.
R&D and preclinical work
R&D and preclinical work is Plus Therapeutics, Inc.’s main cost driver: lab research, formulation work, and translational studies must be funded before any product revenue starts. In 2025, this spending still sat at the core of pipeline progress, with R&D expense absorbing most operating cash and directly shaping the move from early science to human testing.
Radiopharmaceutical manufacturing
Radiopharmaceutical manufacturing is a major cost driver for Plus Therapeutics, Inc. because Rhenium-186 has a 3.72-day half-life, so supply, formulation, and GMP production must move fast and stay tightly controlled. Handling radioactive material raises licensing, shielding, transport, and waste costs, so each batch carries higher compliance and logistics expense.
Regulatory and quality systems
Plus Therapeutics, Inc. must fund FDA submissions, QA, and document control systems, and those costs climb as trial sites and protocol rules grow. As a public, clinical-stage company, it also bears SEC and Sarbanes-Oxley oversight, which makes these costs a fixed drag but a must-have for clinical and commercial readiness.
- Rises with trial complexity
- Includes SEC and QA controls
- Protects launch readiness
G&A and public company costs
Plus Therapeutics, Inc. carries lean but real G&A overhead: salaries, legal, finance, and investor relations sit above R&D, and public listing adds SEC reporting, audit, and compliance work. For a small biotech, those fixed corporate costs can stay material even when revenue is minimal, so cash burn often reflects headcount and public-company fees more than sales scale.
- Public-company reporting adds fixed cost.
- G&A covers core admin salaries.
- Small biotech overhead stays meaningful.
Why Plus Therapeutics Faces a Heavy Cost Structure
Plus Therapeutics, Inc.’s cost base is dominated by R&D, clinical trials, and radiopharmaceutical production. Rhenium-186’s 3.72-day half-life makes GMP manufacturing, cold-chain logistics, and waste handling unusually expensive, while public-company QA, SEC, and SOX controls add fixed overhead.
| Cost item | Driver |
|---|---|
| R&D | Pipeline and lab work |
| Trials | Site, imaging, follow-up |
| Manufacturing | Short-lived isotope logistics |
| G&A | Public reporting and admin |
Revenue Streams
License fees
License fees can bring Plus Therapeutics, Inc. upfront cash plus milestone and royalty income, which is common in biotech deals. The NanoTx agreement is the clearest partnership path here, since licensing is the usual way early-stage drug platforms turn IP into non-dilutive revenue.
Milestone payments
Plus Therapeutics is still pre-commercial, so milestone payments would come from development deals tied to trial or regulatory wins, not product sales. In its latest 2025 filing, the Company reported no commercial revenue, so any milestone cash would directly help offset R&D spend as programs advance.
Future product sales
If R-186 NL or another asset wins approval, Plus Therapeutics, Inc. can shift from a pre-commercial model to hospital and specialty-channel sales, which is how most oncology drugs reach patients. In FY2025, Plus Therapeutics, Inc. had no product revenue, so commercial sales would be the long-term revenue engine.
Future royalties
Future royalties could matter only if Plus Therapeutics, Inc. out-licenses an asset and a partner commercializes it, because royalties usually track net sales and can create recurring, low-capex income. In Plus Therapeutics, Inc.’s 2025 filings, there was no disclosed royalty revenue, so this stream is still pipeline-dependent.
- Royalties follow partner sales.
- No direct manufacturing needed.
- Value starts after commercialization.
Grants and non-dilutive awards
Clinical-stage biotech firms like Plus Therapeutics, Inc. often use grants and non-dilutive awards to fund early research, preclinical work, and rare-cancer trials without issuing new shares. This matters because rare-disease studies can cost millions of dollars before any product revenue arrives, so outside funding helps extend cash runway and reduce dilution risk.
- Funds R and D without equity dilution
- Cuts rare-cancer trial funding pressure
- Supports work before product sales
Plus Therapeutics FY2025: No Product Revenue, Mostly Non-Commercial Cash
Plus Therapeutics, Inc. Revenue Streams in FY2025 were still mostly non-commercial: no product revenue and no disclosed royalty revenue, so cash came mainly from license deals, milestone-linked collaboration income, and grants that fund R&D without equity dilution.
| Stream | FY2025 status |
|---|---|
| Product sales | None |
| Royalties | None disclosed |
| Licenses and milestones | Potential, pipeline-linked |
| Grants | Non-dilutive R&D support |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.